SCHEMBL16707255

SCHEMBL16707255

CC(F)(F)c1cc(NC(=O)c2cc(Cl)ccc2OP(=O)(O)O)cc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TMPRSS4 Q9NRS4 11/20 0.59
▸ P2RX1 P51575 10/20 0.59
▸ P2RX7 Q99572 8/20 0.59
▸ P2RX4 Q99571 7/20 0.59
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ IKBKB O14920 1/20 0.59
▸ CHUK O15111 1/20 0.59
▸ KDR P35968 1/20 0.59
▸ FLT3 P36888 1/20 0.59
▸ MYLK Q15746 1/20 0.59
▸ MAP4K5 Q9Y4K4 1/20 0.59
▸ TLR8 Q9NR97 1/20 0.52
▸ CYP1A2 P05177 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SLC2A1 P11166 1/20 0.47
▸ XPO1 O14980 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6102085 0.94 P2RX1 (0.65) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL28359923 0.93 P2RX1 (0.64) TMPRSS4P2RX1P2RX7P2RX4MEN1
Acetic Acid SCHEMBL28870449 0.92 TMPRSS4 (0.60) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL18073615 0.89 TMPRSS4 (0.56) TMPRSS4P2RX1P2RX7P2RX4MEN1
Dioxane SCHEMBL19586573 0.88 P2RX1 (0.58) TMPRSS4P2RX1P2RX7P2RX4MEN1
SCHEMBL16707257 0.88 TMPRSS4 (0.60) TMPRSS4P2RX1P2RX7P2RX4MEN1
Monoethanolamine SCHEMBL28356005 0.87 P2RX1 (0.57) TMPRSS4P2RX1P2RX7P2RX4MEN1
Monoethanolamine SCHEMBL28105530 0.87 P2RX1 (0.57) TMPRSS4P2RX1P2RX7P2RX4MEN1
Ethyl Acetate SCHEMBL19586419 0.87 TMPRSS4 (0.54) TMPRSS4P2RX1P2RX7P2RX4MEN1
Diethanolamine SCHEMBL29511640 0.86 P2RX1 (0.56) TMPRSS4P2RX1P2RX7P2RX4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873266-B2 Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke AEROMICS, INC. (US) 2024-01-16 — — US disclosed
US-20230293556-A1 PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. (CN) 2023-09-21 — — US disclosed
US-9994514-B2 Methods of treating cerebral edema and spinal cord edema AEROMICS, INC. (US) 2018-06-12 — — US disclosed
US-9949991-B2 Methods of treating aquaporin-mediated conditions AEROMICS, INC. (US) 2018-04-24 — — US disclosed
US-20180042873-A1 NOVEL METHODS AEROMICS, INC. (US) 2018-02-15 — — US disclosed
US-9573885-B2 Methods of treating cerebral edema AEROMICS, INC. (US) 2017-02-21 — — US disclosed
US-20160346302-A1 NOVEL METHODS AEROMICS, INC. (US) 2016-12-01 — — US disclosed
US-20150342967-A1 METHODS AEROMICS, INC. 2015-12-03 — — US disclosed
US-20150133405-A1 Methods AEROMICS, INC. 2015-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150342967-A1 METHODS AQP4, AQP1, AQP3 TMPRSS4 1257/4885P2RX1 2910/4885P2RX7 2817/4885
US-20180042873-A1 NOVEL METHODS AQP4, AQP1, AQP3 TMPRSS4 2568/4885P2RX1 2332/4885P2RX7 2547/4885
US-20160346302-A1 NOVEL METHODS AQP4, AQP1, AQP3 TMPRSS4 2227/4885P2RX1 400/4885P2RX7 552/4885
US-20230293556-A1 PHARMACEUTICAL COMPOSITION OF AQUAPORIN INHIBITOR AND PREPARATION METHOD THEREOF AQP1, AQP4, AQP3 TMPRSS4 2849/4885P2RX1 588/4885P2RX7 455/4885
US-20150133405-A1 Methods AQP4, AQP1, AQP3 TMPRSS4 1257/4885P2RX1 2910/4885P2RX7 2817/4885
US-11873266-B2 Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke AQP4, AQP1, AQP3 TMPRSS4 1444/4885P2RX1 3317/4885P2RX7 3316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback